Research Topics
Species | Katherine S PanageasSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
Neuro Oncol 14:761-7. 2012..01), and frontal lobe predominance (P < .05). Limited level 1 evidence is currently available to guide treatment decisions, and ongoing phase III trials will be critical to understanding the optimal therapy...
When you look matters: the effect of assessment schedule on progression-free survivalKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
J Natl Cancer Inst 99:428-32. 2007..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
Use of high technology imaging for surveillance of early stage breast cancerK S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
Breast Cancer Res Treat 131:663-70. 2012..Strategies to foster judicious utilization of HTRI should be a priority...
An optimal two-stage phase II design utilizing complete and partial response information separatelyKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Control Clin Trials 23:367-79. 2002..Sample size tables are provided for parameter sets commonly used in the oncologic setting. Software is available by contacting the authors...
Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster sizeKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Stat Med 26:2017-35. 2007..By contrast, the cluster weighted GEE method is inefficient...
Analysis of multiple 2x2 tables with site-specific periodontal dataK S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
J Dent Res 82:514-7. 2003..We illustrate these methods using a subset of data from a clinical trial examining the effects of scaling and root planing on levels of interleukin-1 beta...
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman
Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Neuro Oncol 13:649-59. 2011..Combined CT + RT led to longer disease control and survival than did CT or RT alone in cases with no 1p19q deletion. Ongoing trials will address these issues prospectively...
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II studyWen Jen Hwu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 103:2590-7. 2005..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancerArti Hurria
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Drugs Aging 22:785-91. 2005..We sought to determine the association between calculated creatinine clearance (CL(CR)) and grade 3 or 4 toxicities during adjuvant chemotherapy in women > or =65 years of age with breast cancer...
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto
The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 13:1244-51. 2011..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients...
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancerMonica N Fornier
Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:223-7. 2007..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapyArti Hurria
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Am Geriatr Soc 54:1119-24. 2006..To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL)...
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto
The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Neurooncol 105:607-12. 2011..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanomaWen Jen Hwu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 106:2445-51. 2006..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
Patterns of treatment in older adults with primary central nervous system lymphomaKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 110:1338-44. 2007..The objective of the current study was to identify factors associated with the receipt and type of treatment in a population-based cohort of older PCNSL patients...
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer Invest 23:483-7. 2005..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments...
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapyPatrick G Morris
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Leuk Lymphoma 52:1891-7. 2011..51). Similarly, there were no differences in response rates or overall survival according to MTX AUC, suggesting that intra-patient dose escalation to increase MTX exposure is unnecessary when our regimen is utilized...
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 6:55-60. 2005..The activity and safety reported in this trial are consistent with previous reports in similar patients...
KIT as a therapeutic target in metastatic melanomaRichard D Carvajal
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
JAMA 305:2327-34. 2011..We explored the effects of KIT inhibition using imatinib mesylate in this molecular subset of disease...
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanomaWen Jen Hwu
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:3351-6. 2003..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapyMeltem Ekenel
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 113:1025-31. 2008..Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival...
The effect of clustering of outcomes on the association of procedure volume and surgical outcomesKatherine S Panageas
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Ann Intern Med 139:658-65. 2003..Thus, in volume-outcome studies, the degree of clustering of outcomes should be characterized because it may provide insight into variations in quality of care...
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohortElena B Elkin
Health Outcomes Research Group and Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:2757-64. 2006..Our goal was to assess the relationship between adjuvant chemotherapy use and survival in a large, population-based cohort of older women with hormone receptor (HR) -negative breast cancer...
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger
Brain Tumor Center, New York, NY, USA
Ann Neurol 70:163-9. 2011..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)...
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-upLee K Tan
Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 26:1803-9. 2008..However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases...
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanomaMiguel Angel Perales
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 16:2022-9. 2008..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasibleChau Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 8:418-24. 2008..Dose-dense EC (without the 5-FU) is not associated with pneumonitis, and dose-dense paclitaxel (alone) is feasible. Primary objective was feasibility...
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experienceDouglas E Ney
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 116:4605-12. 2010....
Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapyArti Hurria
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Drugs Aging 22:709-15. 2005..CONCLUSIONS: In this cohort of older patients who received chemotherapy for breast cancer, changes in blood counts from cycle 1 to cycle 2 were associated with increased risk of treatment-related grade 3 or 4 toxicity...
Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanomaLeah Ben-Porat
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 106:163-71. 2006....
HDM2 protein overexpression and prognosis in primary malignant melanomaDavid Polsky
Department of Dermatology, Medical Center, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA
J Natl Cancer Inst 94:1803-6. 2002..33 to 0.94; two-sided chi(2) P =.027) in multivariable analysis. HDM2 overexpression appears to be an independent predictor of survival for patients with primary melanoma; however, larger prospective studies are required for validation...
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal studyArti Hurria
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Am Geriatr Soc 54:925-31. 2006..To report on the longitudinal cognitive functioning of older women receiving adjuvant chemotherapy for breast cancer...
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Breast Cancer Res Treat 90:157-63. 2005..CONCLUSION: Imatinib therapy at doses of 800 mg/day was associated with significant toxicity in patients with heavily pre-treated MBC. Our results do not indicate activity for imatinib monotherapy in these unselected patients...
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 27:491-7. 2009..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)...
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxaneMonica N Fornier
Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:1575-9. 2005....
An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanomaCarl R Schmidt
Department of Surgery, Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Surg Oncol 16:948-52. 2009..The pathologic status of the sentinel lymph node (SLN) is a powerful prognostic factor for patients with intermediate thickness melanoma. We hypothesize that a high number of SLNs identified may be associated with poor outcome...
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injectionBrian A Ginsberg
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
Clin Cancer Res 16:4057-65. 2010..To further define the optimal vaccination strategy, we conducted a pilot clinical trial comparing i.m. injection with particle-mediated epidermal delivery (PMED)...
Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomyT Peter Kingham
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Surg Oncol 17:514-20. 2010..This study evaluates the outcome of patients who had a positive SLN but did not undergo CLND at Memorial Sloan-Kettering Cancer Center...
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapyArti Hurria
Memorial Sloan Kettering Cancer Center, NY 10021, New York, USA
Breast Cancer Res Treat 92:151-6. 2005..To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer...
Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinomaRyan C Fields
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 118:3311-20. 2012..Here, the authors describe their experience with a large cohort of patients who were treated at a single institution to describe patterns of recurrence after curative therapy...
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resectionDeborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Surg Oncol 83:68-78; discussion 78-9. 2003..However, the importance of surgeon case volume as a determinant of outcome has been less well studied, and it is unclear whether hospital or surgeon volume is the more powerful predictor of outcomes...
Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institutionRyan C Fields
Gastric and Mixed Tumor Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Surg Oncol 18:2529-37. 2011..Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine neoplasm with propensity for lymphatic spread. The rarity of MCC has limited analysis of factors associated with a positive sentinel lymph node biopsy (SLNB) and survival...
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trialWen Jen Hwu
Departments of Medicine, Epidemiology and Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2610-5. 2002..To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma...
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanomaJedd D Wolchok
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 15:2044-50. 2007..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
Bcl-6 predicts improved prognosis in primary central nervous system lymphomaOren Levy
Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA
Cancer 112:151-6. 2008..The objectives of this study were to characterize the immunophenotypes of PCNSL samples and to determine their utility in predicting clinical outcomes...
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabJianda Yuan
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
Proc Natl Acad Sci U S A 108:16723-8. 2011....
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survivalGeoffrey Y Ku
Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 116:1767-75. 2010..The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan-Kettering Cancer Center...
Patterns of care in elderly glioblastoma patientsFabio M Iwamoto
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Neurol 64:628-34. 2008..To evaluate the patterns of care in elderly glioblastoma (GBM) patients from a large population-based registry...
Prognosis and patterns of care in elderly patients with gliomaFabio M Iwamoto
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer 115:5534-40. 2009..The current study was conducted to evaluate the patterns of care and survival of older adults with oligodendroglioma (OLI) and astrocytoma (AST) from a large population-based registry...
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancerMaura N Dickler
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:7878-83. 2008..To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway...
Cancer screening among patients with advanced cancerCamelia S Sima
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, Second Floor, New York, NY 10065, USA
JAMA 304:1584-91. 2010..Cancer screening has been integrated into routine primary care but does not benefit patients with limited life expectancy...
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resectionDeborah Schrag
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 98:163-71. 2006..e., hospital or surgeon) procedure volumes and patient outcomes have been demonstrated for many types of cancer operation. We performed a population-based cohort study to examine these associations for ovarian cancer resections...
Variates of survival in metastatic uveal melanomaPetra Rietschel
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 23:8076-80. 2005..Data on variates of survival and site of first metastasis may guide strategies for screening patients, although our data failed to show a survival advantage in discovering asymptomatic metastatic disease...
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic modelLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:5711-5. 2006....
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancerChau T Dang
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:5754-61. 2004..The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival...
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 10:4062-7. 2004..CONCLUSIONS: Celecoxib combined with trastuzumab is well tolerated. However, this combination in patients with HER2/neu-overexpressing, trastuzumab-refractory disease, was not active...
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapyPatrick G Morris
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Thorac Oncol 7:382-5. 2012..A retrospective review was carried out to assess the impact of whole brain radiotherapy (WBRT), intrathecal therapy (IT), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on outcomes...
Utility of lesion diameter in the clinical diagnosis of cutaneous melanomaNaheed R Abbasi
Ronald O Perelman Department of Dermatology, New York University School of Medicine, 550 First Ave, Room H 100, New York, NY 10016, USA
Arch Dermatol 144:469-74. 2008..To determine the utility of the current diameter criterion of larger than 6 mm of the ABCDE acronym for the early diagnosis of cutaneous melanoma...
Systemic high-dose intravenous methotrexate for central nervous system metastasesAndrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Neurooncol 78:255-60. 2006..Rapid infusion of high-dose intravenous methotrexate (HD IV MTX) penetrates the blood-brain barrier (BBB) and has reported activity in leptomeningeal metastases...
Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node statusCristina R Ferrone
Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Ann Surg Oncol 9:637-45. 2002..However, patients with TCM are prognostically heterogeneous, and all independently predictive factors should be considered when an individual patient's risk of recurrence is assessed...
PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferationMaryann Mikhail
Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
Clin Cancer Res 11:5153-7. 2005..Our findings show the need to examine molecular alterations identified in preclinical studies using an adequately large cohort of patients with extended follow-up to better assess the magnitude of their clinical relevance...
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysisKatherine S Panageas
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:2466-72. 2005..Although results from clinical trials suggest progress in the treatment of PCNSL, survival improvements are not reflected in this population-based cohort...
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemiaTodd L Rosenblat
Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 16:5303-11. 2010..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
Geographic access and the use of screening mammographyElena B Elkin
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Med Care 48:349-56. 2010..Inadequate mammography resources in some areas may impair access to this technology. We assessed the relationship between availability of mammography machines and the use of screening...
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancerShanu Modi
Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:3665-73. 2002..07). CONCLUSION: Patients with evidence of tumor response on paclitaxel had a QoL benefit not observed in nonresponders, and this response was associated with a trend for lower overall costs...
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivoEmanuela Romano
Laboratory of Cellular Immunobiology, Immunology Program, Sloan Kettering Institute for Cancer Research, New York, New York, USA
Clin Cancer Res 17:1984-97. 2011..We compared the efficacy of human Langerhans cells (LC) as tumor immunogens in vivo with monocyte-derived dendritic cells (moDC) and investigated how interleukin 15 (IL15) supports optimal DC-stimulated antitumor immunity...
Clinicopathological features of and risk factors for multiple primary melanomasCristina R Ferrone
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
JAMA 294:1647-54. 2005..9% at 5 years. CONCLUSIONS: The incidence of MPM is increased in patients with a positive family history and/or dysplastic nevi. These patients should undergo intensive dermatologic screening and should consider genetic testing...
A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapyMichael W Kattan
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 101:2509-15. 2004....
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune responseGabrielle A Rizzuto
Departments of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Exp Med 206:849-66. 2009..Further, precursor frequency as an isolated variable can be exploited to augment efficacy of clinical vaccine strategies designed to activate any antigen-specific CD8(+) T cells...
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanomaDavid B Solit
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 14:8302-7. 2008..We conducted a phase II trial using the hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in melanoma patients. The primary end points were clinical responses and whether treatment inhibited MAPK pathway activity...
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanomaRebecca C Taylor
Departments of Surgery, Biostatistics, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 25:869-75. 2007..The prognostic implications of TILs were re-evaluated in a large group of patients undergoing SLN biopsy at our institution...
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based dataCami S Sima
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Appl Health Econ Health Policy 8:37-51. 2010....
Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanomaCarole Hazan
Ronald O. Perelman Department of Dermatology, New York University School of Medicine/Veterans Affairs Medical Center, 550 First Avenue, New York, NY 10010, USA
Cancer 95:634-40. 2002..CONCLUSIONS: In primary cutaneous melanoma, a high proliferative index is associated with clinicopathologic parameters predictive of worse clinical outcomes. However, it was not an independent predictor of clinical outcome...
Developing a cancer-specific geriatric assessment: a feasibility studyArti Hurria
Department of Medicine, Psychiatry and Behavioral Sciences, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:1998-2005. 2005....
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-responseGeorge Sgouros
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Nucl Med 44:260-8. 2003....
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomasAdilia Hormigo
Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Clin Cancer Res 12:5698-704. 2006..We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers...
A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in menAnne S Reiner
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
Breast Cancer Res Treat 130:301-6. 2011..Lymphedema is a common complication affecting men with breast cancer as well as women and appropriate treatment and rehabilitation strategies need to be implemented for both genders...
(124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo
Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Nucl Med 52:1173-80. 2011..We also determined the biodistribution of (124)I-huA33 when a large dose of human intravenous IgG (IVIG) was administered to manipulate the Fc receptor or when (124)I-huA33 was given via hepatic arterial infusion (HAI)...
How to build and interpret a nomogram for cancer prognosisAlexia Iasonos
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
J Clin Oncol 26:1364-70. 2008..This guide provides a nonstatistical audience with a methodological approach for building, interpreting, and using nomograms to estimate cancer prognosis or other health outcomes...
Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader communityLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
Leuk Lymphoma 47:2449-52. 2006..We have sought to elaborate some potential causes of these disparities; however, future studies are needed to identify and address specific barriers to care in the community...
Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancerCatherine Van Poznak
Breast Cancer Medicine Service, The Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:2319-26. 2002..g., HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study...
A statistical perspective on gene expression data analysisJaya M Satagopan
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Stat Med 22:481-99. 2003..S-plus and SAS codes to perform the statistical methods are provided. Gene expression data from an unpublished oncologic study is used to illustrate these methods...
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidJae H Park
Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 118:1248-54. 2011..These data highlight a need to educate health care providers across a wide range of medical fields, who may be the first to evaluate patients with APL, to have a major effect on early death and the cure rate of APL...
Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative studyEdi Brogi
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 98:2170-6. 2003..Ductal lavage (DL) is a new method for the sampling of breast epithelium. Data regarding its sensitivity in the detection of epithelial abnormalities, including carcinoma in situ (CIS), remains limited...
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resectionDeborah Schrag
Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Ann Surg 236:583-92. 2002..To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer...
Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanomaWilliam G Hawkins
Department of Surgery, Washington University, St. Louis, Missouri 63110, USA
Ann Surg Oncol 12:207-13. 2005..Tumors with prominent fibrosis (pure subtype) are unlikely to disseminate to regional lymph nodes and are associated with a favorable outcome when compared with those with mixed desmoplasia or CM...
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvantsSusanne G Schaed
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 8:967-72. 2002....
Delayed neurotoxicity in primary central nervous system lymphomaAntonio M P Omuro
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Arch Neurol 62:1595-600. 2005....
Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphomaTeri N Kreisl
Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
Leuk Lymphoma 49:1710-6. 2008..028). Despite improved treatment for both diseases over the past decade, survival remains dismal in this cohort of Medicare/Medicaid beneficiaries with HIV-related PCNSL. These results may not apply to the general HIV population...
Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsyKimberly Moore Dalal
Department of Surgery, David Grant United States Air Force Medical Center, Travis AFB, CA, USA
Ann Surg Oncol 15:2206-14. 2008..An understanding of the methods of detection of recurrent melanoma after sentinel lymph node biopsy (SLNB) is essential for the coordination of a rational plan of follow-up...
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemiaNicole Lamanna
Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 24:1575-81. 2006..Based on these results, we are currently studying PCR as initial therapy for patients with CLL...
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical featuresJeffrey J Raizer
Feinberg School of Medicine, Department of Neurology, Northwestern University, 710 North Lake Shore Drive, Chicago, IL 60611, USA
Neuro Oncol 10:199-207. 2008..The prognostic factors identified in this retrospective study should be considered when making treatment decisions for patients with BM and used as stratification factors in future clinical trials...
Treatment of spinal involvement in neuroblastoma patientsDavid I Sandberg
Department of Surgery, Division of Neurosurgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, N.Y. 10021, USA
Pediatr Neurosurg 39:291-8. 2003..Chemotherapy may be avoided in low-risk patients who are offered potentially curative operations. Patients treated with operations for epidural disease are at high risk of subsequently developing spinal deformity...
Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1Cristina Musselli
Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Cancer 97:660-7. 2002..Assuming this criteria, convincing induction of T-cell immunity against MUC1 by vaccination has yet to be described...
Results of preoperative embolization for metastatic spinal neoplasmsVikram C Prabhu
Section of Neurosurgery, University of Nebraska Medical Center, Omaha, Nebraska, USA
J Neurosurg 98:156-64. 2003..Superselective catheterization permits Grade D or E embolization in 80% of patients. Shared blood supply with an RMA is the most important factor precluding complete embolization...
Research Grants
- Analysis Methods for Volume-Outcome StudiesKatherine Panageas; Fiscal Year: 2005..Our methodological research will heighten awareness of clustering in health policy studies. Upon completion of our research plan, we will make recommendations about various analytic strategies for clustered binary data. ..
